Read by QxMD icon Read

FET PET glioblastoma

Garry Ceccon, Lazaros Lazaridis, Gabriele Stoffels, Marion Rapp, Manuel Weber, Tobias Blau, Phillip Lohmann, Sied Kebir, Ken Herrmann, Gereon R Fink, Karl-Josef Langen, Martin Glas, Norbert Galldiks
PURPOSE: We present our first clinical experience with O-(2-18 F-fluoroethyl)-L-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes. METHODS: We retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes...
March 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Francesca Pasi, Marco Giovanni Persico, Federica Eleonora Buroni, Carlo Aprile, Marina Hodolic, Franco Corbella, Rosanna Nano, Angelica Facoetti, Lorenzo Lodola
The differential diagnosis between recurrence of gliomas or brain metastases and this phenomenon is important in order to choose the best therapy and predict the prognosis but is still a big problem for physicians. The new emerging MRI, CT, and PET diagnostic modalities still lack sufficient accuracy. Radiolabeled choline and amino acids have been reported to show great tumor specificity. We studied the uptake kinetics of [(18)F]fluoromethyl-choline (FCH) and O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET) by the T98G human glioblastoma cells from 20 to 120 min after irradiation either with photons at 2-10-20 Gy or with carbon ions at 2 Gy (at the National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy)...
2017: Contrast Media & Molecular Imaging
Antoine Verger, Gabriele Stoffels, Elena K Bauer, Philipp Lohmann, Tobias Blau, Gereon R Fink, Bernd Neumaier, Nadim J Shah, Karl-Josef Langen, Norbert Galldiks
PURPOSE: The molecular features isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion have gained major importance for both glioma typing and prognosis and have, therefore, been integrated in the World Health Organization (WHO) classification in 2016. The aim of this study was to characterize static and dynamic O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET parameters in gliomas with or without IDH mutation or 1p/19q co-deletion. METHODS: Ninety patients with newly diagnosed and untreated gliomas with a static and dynamic (18)F-FET PET scan prior to evaluation of tumor tissue according to the 2016 WHO classification were identified retrospectively...
October 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
Bogdana Suchorska, Armin Giese, Annamaria Biczok, Marcus Unterrainer, Michael Weller, Mark Drexler, Peter Bartenstein, Ulrich Schüller, Jörg-Christian Tonn, Nathalie L Albert
Background: Stratification of glioma according to isocitrate dehydrogenase 1/2 (IDH1/2) mutation and 1p/19q codeletion status has gained major importance in the new World Health Organization (WHO) classification. Parameters derived from uptake dynamics of 18F-fluoro-ethyl-tyrosine PET (18F-FET-PET) such as minimal time-to-peak (TTPmin) allow discrimination between different prognostic glioma subgroups, too. The present study is aimed at exploring whether TTPmin analysis provides prognostic information beyond the WHO classification...
January 22, 2018: Neuro-oncology
Marie Anne Richard, Jérémie P Fouquet, Réjean Lebel, Martin Lepage
O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) is a radiolabeled artificial amino acid used in PET for tumor delineation and grading. The present study compares different kinetic models to determine which are more appropriate for (18)F-FET in rats. Methods: Rats were implanted with F98 glioblastoma cells in the right hemisphere and scanned 9-15 d later. PET data were acquired during 50 min after a 1-min bolus of (18)F-FET. Arterial blood samples were drawn for arterial input function determination. Two compartmental pharmacokinetic models were tested: the 2-tissue model and the 1-tissue model...
August 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Carina Stegmayr, Dennis Oliveira, Nicole Niemietz, Antje Willuweit, Philipp Lohmann, Norbert Galldiks, N Jon Shah, Johannes Ermert, Karl-Josef Langen
Restoration of the blood-brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression. This so-called pseudoresponse is difficult to differentiate from a true tumor response with conventional MRI. Initial patient studies have indicated that PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) may be helpful for solving this diagnostic problem. This study was performed to investigate the effects of bevacizumab on BBB permeability and (18)F-FET uptake in a human xenograft model...
May 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Michael Lundemann, Junia Cardoso Costa, Ian Law, Svend Aage Engelholm, Aida Muhic, Hans Skovgaard Poulsen, Per Munck Af Rosenschold
BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18 F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients. MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol ). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria...
March 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Oliver Oehlke, Michael Mix, Erika Graf, Tanja Schimek-Jasch, Ursula Nestle, Irina Götz, Sabine Schneider-Fuchs, Astrid Weyerbrock, Irina Mader, Brigitta G Baumert, Susan C Short, Philipp T Meyer, Wolfgang A Weber, Anca-Ligia Grosu
BACKGROUND: The higher specificity of amino-acid positron emission tomography (AA-PET) in the diagnosis of gliomas, as well as in the differentiation between recurrence and treatment-related alterations, in comparison to contrast enhancement in T1-weighted MRI was demonstrated in many studies and is the rationale for their implementation into radiation oncology treatment planning. Several clinical trials have demonstrated the significant differences between AA-PET and standard MRI concerning the definition of the gross tumor volume (GTV)...
October 5, 2016: BMC Cancer
Carina Stegmayr, Ulrike Bandelow, Dennis Oliveira, Philipp Lohmann, Antje Willuweit, Christian Filss, Norbert Galldiks, Joachim H R Lübke, N Jon Shah, Johannes Ermert, Karl-Josef Langen
PURPOSE: O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on (18)F-FET uptake in two rat glioma models and one human xenograft model. METHODS: F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex)...
March 2017: European Journal of Nuclear Medicine and Molecular Imaging
Julie Bolcaen, Kelly Lybaert, Lieselotte Moerman, Benedicte Descamps, Karel Deblaere, Tom Boterberg, Jean-Pierre Kalala, Caroline Van den Broecke, Filip De Vos, Christian Vanhove, Ingeborg Goethals
BACKGROUND: Discrimination between glioblastoma (GB) and radiation necrosis (RN) post-irradiation remains challenging but has a large impact on further treatment and prognosis. In this study, the uptake mechanisms of 18F-fluorodeoxyglucose (18F-FDG), 18F-fluoroethyltyrosine (18F-FET) and 18F-fluoromethylcholine (18F-FCho) positron emission tomography (PET) tracers were investigated in a F98 GB and RN rat model applying kinetic modeling (KM) and graphical analysis (GA) to clarify our previous results...
2016: PloS One
Sidsel Højklint Poulsen, Thomas Urup, Kirsten Grunnet, Ib Jarle Christensen, Vibeke Andrée Larsen, Michael Lundemann Jensen, Per Munck Af Rosenschöld, Hans Skovgaard Poulsen, Ian Law
BACKGROUND: Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker. METHODS: We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning...
March 2017: European Journal of Nuclear Medicine and Molecular Imaging
Adrien Holzgreve, Matthias Brendel, Song Gu, Janette Carlsen, Erik Mille, Guido Böning, Giorgia Mastrella, Marcus Unterrainer, Franz J Gildehaus, Axel Rominger, Peter Bartenstein, Roland E Kälin, Rainer Glass, Nathalie L Albert
Noninvasive tumor growth monitoring is of particular interest for the evaluation of experimental glioma therapies. This study investigates the potential of positron emission tomography (PET) using O-(2-(18)F-fluoroethyl)-L-tyrosine ([(18)F]-FET) to determine tumor growth in a murine glioblastoma (GBM) model-including estimation of the biological tumor volume (BTV), which has hitherto not been investigated in the pre-clinical context. Fifteen GBM-bearing mice (GL261) and six control mice (shams) were investigated during 5 weeks by PET followed by autoradiographic and histological assessments...
2016: Frontiers in Neuroscience
Maciej Harat, Bogdan Małkowski, Roman Makarewicz
BACKGROUND AND PURPOSE: The diagnostic accuracy of magnetic resonance imaging (MRI) for glioblastoma multiforme (GBM) is suboptimal. We analysed pre-treatment MRI- and dual time-point 18F-fluoroethylthyrosine-PET (FET-PET)-based target volumes and GBM recurrence patterns following radiotherapy with temozolomide. MATERIALS AND METHODS: Thirty-four patients with primary GBM were treated according to MRI-based treatment volumes (GTVRM). Patients underwent dual time-point FET-PET scans prior to treatment, and biological tumour volumes (GTVPET) were contoured but not used for target definition...
August 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Marc D Piroth, Norbert Galldiks, Michael Pinkawa, Richard Holy, Gabriele Stoffels, Johannes Ermert, Felix M Mottaghy, N Jon Shah, Karl-Josef Langen, Michael J Eble
BACKGROUND: O-(2-18 F-fluoroethyl)-L-tyrosine-(FET)-PET may be helpful to improve the definition of radiation target volumes in glioblastomas compared with MRI. We analyzed the relapse patterns in FET-PET after a FET- and MRI-based integrated-boost intensity-modulated radiotherapy (IMRT) of glioblastomas to perform an optimized target volume definition. METHODS: A relapse pattern analysis was performed in 13 glioblastoma patients treated with radiochemotherapy within a prospective phase-II-study between 2008 and 2009...
June 24, 2016: Radiation Oncology
Marco Giovanni Persico, Federica Eleonora Buroni, Francesca Pasi, Lorenzo Lodola, Carlo Aprile, Rosanna Nano, Marina Hodolic
BACKGROUND: Despite complex treatment of surgery, radiotherapy and chemotherapy, high grade gliomas often recur. Differentiation between post-treatment changes and recurrence is difficult. (18)F-methyl-choline ((18)F-FCH) is frequently used in staging and detection of recurrent prostate cancer disease as well as some brain tumours; however accumulation in inflammatory tissue limits its specificity. The (18)F-ethyl-tyrosine ((18)F-FET) shows a specific uptake in malignant cells, resulting from increased expression of amino acid transporters or diffusing through the disrupted blood-brain barrier...
June 1, 2016: Radiology and Oncology
Philip J O'Halloran, Thomas Viel, David W Murray, Lydia Wachsmuth, Katrin Schwegmann, Stefan Wagner, Klaus Kopka, Monika A Jarzabek, Patrick Dicker, Sven Hermann, Cornelius Faber, Tim Klasen, Michael Schäfers, David O'Brien, Jochen H M Prehn, Andreas H Jacobs, Annette T Byrne
PURPOSE: Resistance to bevacizumab (BEV) in glioblastoma is believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET molecular imaging biomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235. METHODS: Tumours were established by orthotopically implanting U87MG-luc2 cells in mice. Animals were treated with BEZ235 and/or BEV, and imaged using diffusion-weighted-MRI, T2-weighted and T2*-weighted before and after administration of superparamagnetic iron oxide contrast agent...
August 2016: European Journal of Nuclear Medicine and Molecular Imaging
Mette Kjoelhede Nedergaard, Signe Regner Michaelsen, Lara Perryman, Janine Erler, Hans Skovgaard Poulsen, Marie-Thérése Stockhausen, Ulrik Lassen, Andreas Kjaer
BACKGROUND: The radiolabeled amino acid O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) and thymidine analogue 3'-deoxy-3'-(18)F-fluorothymidine (FLT) are widely used for positron emission tomography (PET) brain tumor imaging; however, comparative studies are scarce. The aim of this study therefore was to compare FLT and FET PET for the assessment of anti-VEGF response in glioblastoma xenografts. METHODS: Xenografts with confirmed intracranial glioblastoma were treated with anti-VEGF therapy (B20-4...
March 2016: Nuclear Medicine and Biology
Constantin Lapa, Katharina Lückerath, Irene Kleinlein, Camelia Maria Monoranu, Thomas Linsenmann, Almuth F Kessler, Martina Rudelius, Saskia Kropf, Andreas K Buck, Ralf-Ingo Ernestus, Hans-Jürgen Wester, Mario Löhr, Ken Herrmann
Chemokine receptor-4 (CXCR4) has been reported to be overexpressed in glioblastoma (GBM) and to be associated with poor survival. This study investigated the feasibility of non-invasive CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine receptor ligand (68)Ga-Pentixafor. 15 patients with clinical suspicion on primary or recurrent glioblastoma (13 primary, 2 recurrent tumors) underwent (68)Ga-Pentixafor-PET/CT for assessment of CXCR4 expression prior to surgery...
2016: Theranostics
Niels Buchmann, Benjamin Kläsner, Jens Gempt, Jan Stefan Bauer, Thomas Pyka, Claire Delbridge, Bernhard Meyer, Bernd Joachim Krause, Florian Ringel
OBJECTIVE: Complete resection of contrast-enhancing tumor is an important prognostic factor in glioblastoma therapy. The current clinical standard for control of resection is magnetic resonance imaging (MRI). (18)F-Fluoroethyl-l-thyrosine (FET) is a positron emission tomography (PET) radiopharmaceutical applicable for widespread use because of its long half-life radionuclide. We assessed the sensitivity of postoperative MRI versus FET-PET to detect residual tumor and the impact of the time interval between resection and FET-PET...
May 2016: World Neurosurgery
Erik S Mittra, Norman Koglin, Camila Mosci, Meena Kumar, Aileen Hoehne, Khun Visith Keu, Andrei H Iagaru, Andre Mueller, Mathias Berndt, Santiago Bullich, Matthias Friebe, Heribert Schmitt-Willich, Volker Gekeler, Lüder M Fels, Claudia Bacher-Stier, Dae Hyuk Moon, Frederick T Chin, Andrew W Stephens, Ludger M Dinkelborg, Sanjiv S Gambhir
PURPOSE: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a novel radiopharmaceutical for Positron Emission Tomography (PET) imaging. It is a glutamate analogue that can be used to measure xC- transporter activity. This study was performed to assess the feasibility of 18F-FSPG for imaging orthotopic brain tumors in small animals and the translation of this approach in human subjects with intracranial malignancies. EXPERIMENTAL DESIGN: For the small animal study, GS9L glioblastoma cells were implanted into brains of Fischer rats and studied with 18F-FSPG, the 18F-labeled glucose derivative 18F-FDG and with the 18F-labeled amino acid derivative 18F-FET...
2016: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"